To access the session recording, navigate to the content tab and click the view video button. 

Session Schedule

Find a specific presentation in the session by navigating to the timestamp indicated below.

0:00:00
Introduction

0:01:20
Prostate cancer, prostate-specific antigen, and obstructive sleep apnea: What do we know so far?
Allan Porcacchia (Brazil)

0:18:37
Sleep disorders and circadian disruption: Clinical insights into Cancer risk and progression
Maria Paola Mogavero (Italy)

0:38:21
Sleep disruption in patients with Cancer
Saadia Faiz (United States)

0:56:55
Question and answer

Summary
Cancer is a major public health concern worldwide, responsible for almost 1 in 6 deaths according to data from the International Agency for Research on Cancer (IARC). By 2050, estimates suggest that there will be around 35 million new cases of cancer each year. In parallel, sleep disorders have become more prevalent along with circadian disruptions. Insomnia and obstructive sleep apnea (OSA) have independent prevalence rates of close to 30% and are associated with other health problems. Recently, shift work was recognized as “probably carcinogenic to humans”, further emphasizing the importance of good quality sleep for overall health and preventing serious diseases. Several investigations have shown a potential association between sleep disorders and a higher risk for cancer, while others have been focusing on the impact of circadian misalignment on cancer-related fatigue or on the efficacy of chemotherapies. Also, clinical studies employing the chronotherapeutic approach have shown promising results in the treatment of some types of cancer. Thus, this symposium represents a timely opportunity to present recent data from animal and population-based studies evaluating sleep disorders and cancer risk, as well as the impact of circadian rhythm on both cancer treatments response and cancer-related fatigue. It aims to be a space for discussion of possible biological mechanisms intrinsic to both health conditions, focusing on OSA, insomnia and circadian disruptions.